Cite
P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
MLA
Sandra Huber, et al. “P694: Risk Assessment According to Ipss-M Is Superior to Aml Eln 2022 Risk Classification in Mds/Aml Patients Defined by Icc – Is an Inclusion into Aml Trials Justified?” HemaSphere, vol. 7, Aug. 2023. EBSCOhost, https://doi.org/10.1097/01.HS9.0000969680.24060.be.
APA
Sandra Huber, Constance Baer, Stephan Hutter, Frank Dicker, Manja Meggendorfer, Christian Pohlkamp, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach, & Gregor Hoermann. (2023). P694: Risk Assessment According to Ipss-M Is Superior to Aml Eln 2022 Risk Classification in Mds/Aml Patients Defined by Icc – Is an Inclusion into Aml Trials Justified? HemaSphere, 7. https://doi.org/10.1097/01.HS9.0000969680.24060.be
Chicago
Sandra Huber, Constance Baer, Stephan Hutter, Frank Dicker, Manja Meggendorfer, Christian Pohlkamp, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach, and Gregor Hoermann. 2023. “P694: Risk Assessment According to Ipss-M Is Superior to Aml Eln 2022 Risk Classification in Mds/Aml Patients Defined by Icc – Is an Inclusion into Aml Trials Justified?” HemaSphere 7 (August). doi:10.1097/01.HS9.0000969680.24060.be.